Match!
The Journal of Nuclear Medicine
IF
7.31
Papers
30192
Papers 10000
1 page of 1,000 pages (10k results)
Newest
#1Domninc Bagguley (Peter MacCallum Cancer Centre)
#2Marcus Cumberbatch (Peter MacCallum Cancer Centre)
Last. Declan G. Murphy (Peter MacCallum Cancer Centre)H-Index: 78
view all 4 authors...
Source
#1Frederik L. Giesel (University Hospital Heidelberg)H-Index: 38
#2Sebastian Adeberg (Heidelberg University)H-Index: 6
Last. Stefan Rieken (University Hospital Heidelberg)H-Index: 26
view all 18 authors...
68Ga-FAPI-2/4/46 have already been proposed as promising PET-tracers. However, the short half-life of 68Ga (T1/2 68 min) creates problems with manufacture and delivery. 18F (T1/2 110 min) labeling would result in a more practical large scale production and a cold-kit formulation would improve the spontaneous availability. The NOTA-chelator ligand FAPI-74 can be labeled with both 18F-AlF (Aluminum-Fluoride) and 68Ga. Here we describe the in-vivo evaluation of 18F-FAPI-74 and a proof-of-mechanism ...
Source
#1Johannes Czernin (UCLA: University of California, Los Angeles)H-Index: 73
Source
#1Lanell M. Peterson (UW: University of Washington)H-Index: 26
#2Brenda F. Kurland (University of Pittsburgh)H-Index: 32
Last. Kenneth Krohn (OHSU: Oregon Health & Science University)H-Index: 10
view all 13 authors...
RATIONALE Histone deacetylase inhibitors (HDACi) may overcome endocrine resistance in estrogen receptor positive (ER+) metastatic breast cancer. We tested whether 18F-Fluoroestradiol (18F-FES)-PET imaging would elucidate pharmacodynamics of combination HDACi and endocrine therapy. Methods: Patients with ER+/HER2- metastatic breast cancer with prior clinical benefit from endocrine therapy but later progression on aromatase inhibitor (AI) therapy were given vorinostat (400mg daily) sequentially or...
Source
#1Caren van Roekel (UU: Utrecht University)H-Index: 1
#2Remco Bastiaannet (UU: Utrecht University)H-Index: 3
Last. Marnix G.E.H. Lam (UU: Utrecht University)H-Index: 27
view all 8 authors...
INTRODUCTION: Radioembolization is a treatment option for colorectal cancer (CRC) patients with inoperable, chemorefractory hepatic metastases. Personalized treatment requires established dose thresholds. Hence, the aim of this study was to explore the relation between dose and effect (i.e. response and toxicity) in CRC patients treated with holmium-166 (166Ho) radioembolization. MATERIALS AND METHODS: CRC patients treated in the HEPAR II and SIM studies were analyzed. Absorbed doses were estima...
Source
#1Lionel S. Zuckier (Montefiore Medical Center)H-Index: 1
#1Lionel S. ZuckierH-Index: 16
Last. Leonard M. FreemanH-Index: 17
view all 4 authors...
No abstract available Keywords: COVID-19; Infectious Disease; Respiratory; Vascular; perfusion scintigraphy; pulmonary embolism.
Source
#1Johannes Czernin (UCLA: University of California, Los Angeles)H-Index: 73
Source
Source
#1Lisa Bodei (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 12
#1Lisa BodeiH-Index: 40
Last. Jens T. SivekeH-Index: 33
view all 13 authors...
Source
Introduction: Fixed-dose pembrolizumab (200 mg abs., d1, q3w) for the treatment of malignant pleural mesothelioma did not result in survival benefit in the phase 3 PROMISE-meso trial compared to 2nd-line chemotherapy. Due to lack of validated imaging response criteria, responder-subgroups with potential survival benefit have not yet been identified. Here, we administered high-dose pembrolizumab (10 mg/kg, d1, q2w) considering the KEYNOTE-028 trial and assessed the prognostic value of PET metabol...
Source
12345678910
Top fields of study
Radiology
PET-CT
Pathology
Chemistry
Nuclear medicine
Medicine